Are you Megu Yamaguchi Baden?

Claim your profile

Publications (7)9.01 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVE: Serum adiponectin levels are affected by gender, body fat mass, several pathological factors, or therapeutic interventions and it might be also affected by age. This study aimed to investigate the relationship between serum adiponectin levels and age in several physiological states. DESIGN, PATIENTS AND MEASUREMENTS: The study was carried out in 21,100 healthy subjects (12,363 men and 8,737 women) and 1,833 patients with type 2 diabetes (1,233 men and 600 women). Physical and demographic characteristics were recorded, and blood samples were collected to measure serum adiponectin levels. Using these data, we determined the relationships between serum adiponectin levels and various parameters, including age. RESULTS: Serum adiponectin levels increased with increasing age of healthy subjects and in patients with diabetes, in both men and women. Serum adiponectin levels were positively correlated with age in healthy subjects and patients with diabetes, in both men and women. In stepwise multiple regression analysis with serum adiponectin levels as the dependent variable and physiological characteristics as explanatory variables, age was significantly and independently associated with serum adiponectin levels in each of these groups of subjects. CONCLUSIONS: Serum adiponectin levels are significantly and positively associated with age in healthy subjects and in patients with diabetes. This association is independent of renal function, body fat status, glucose metabolism and lipid profiles. © 2012 Blackwell Publishing Ltd.
    Clinical Endocrinology 09/2012; · 3.40 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVE: With the increasing prevalence of diseases related to obesity, metabolic syndrome and its key player adiponectin are now attracting considerable attention. Hypoadiponectinemia is reported to be a risk factor for hypertension and associated with endothelial dysfunction, which is closely related to complications of obesity such as hypertension. As there is limited information regarding serum adiponectin levels in normotensive people, we undertook the large-scale study to determine the association of adiponectin with blood pressure in mainly normotensive people. DESIGN, PATIENTS AND MEASUREMENTS: In 21,100 Japanese adults (12,363 men and 8,737 women) who had no apparent diseases, we examined the relationship between the serum adiponectin concentration and blood pressure by performing a questionnaire survey, physical measurements, and measurement of laboratory parameters including the serum adiponectin level. RESULTS: Subjects with hypoadiponectinemia had higher systolic and diastolic blood pressures as already reported. And interestingly, subjects with higher adiponectin had lower systolic and diastolic blood pressure. According to linear regression analysis, adiponectin showed a significant negative correlation with systolic and diastolic blood pressure independently of the other variables. Analysis of covariance according to adiponectin quintiles showed that systolic and diastolic blood pressure in highest adiponectin quintile was significantly lower than other quintiles. CONCLUSIONS: The present study revealed that there were significant trends toward lower systolic and diastolic blood pressure with higher adiponectin not only in hepertensive people but also in normotensive people. © 2012 Blackwell Publishing Ltd.
    Clinical Endocrinology 02/2012; · 3.40 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To investigate the relationship between serum levels of cystatin C and adiponectin in patients with type 2 diabetes. We examined serum cystatin C and adiponectin levels in 234 patients with type 2 diabetes who visited our hospital. The serum level of cystatin C was positively correlated with age (P < 0.001), duration of diabetes (P = 0.013), serum creatinine (P < 0.001), uric acid (P < 0.001), and adiponectin (p = 0.001), while it was inversely correlated with estimated glomerular filtration rate (P < 0.001). Serum adiponectin was significantly higher in patients with high serum cystatin C levels than in those with normal cystatin C levels (8.3 ± 4.7 and 6.2 ± 3.2 μg/mL, respectively; P < 0.001). Adiponectin was also significantly higher in male patients with high cystatin C levels, but not in females. In multiple regression analysis, serum adiponectin was also independently and significantly correlated to age, diastolic blood pressure, high-density lipoprotein cholesterol, triglyceride and serum cystatin C. Serum adiponectin level was correlated with serum cystatin C level on simple and multiple regression analyses in patients with type 2 diabetes. Although circulating adiponectin is increased in advanced kidney disease, it might be biologically inactive due to binding to cystatin C and thus not display an anti-arteriosclerotic effect.
    Clinical and Experimental Nephrology 11/2011; 16(3):399-405. · 1.25 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Along with the increasing prevalence of obesity and related diseases, particularly atherosclerotic diseases, metabolic syndrome (MetS) is now a common and major public health issue in many countries around the world. Adiponectin, a protein secreted by the adipose tissue, has become recognized as a key player in the development of MetS. These days, not only MetS but also borderline metabolic/physiological abnormalities, such as impaired fasting glucose, high normal blood pressure and high normal plasma cholesterol, have been reported to be risk factors for atherosclerotic disease. Therefore, we undertook this study to determine the relationship between adiponectin and borderline metabolic/physiological abnormalities, as well as MetS.
    Nutrition & Diabetes. 09/2011; 1(10):e18.
  • [Show abstract] [Hide abstract]
    ABSTRACT: A 66-year-old man with Cushing's syndrome due to adrenocorticotropin-independent bilateral macronodular adrenocortical hyperplasia (AIMAH) was treated for 7 years with trilostane, a 3β-hydroxysteroid dehydrogenase inhibitor. Administration of trilostane reduced the serum cortisol level to around the upper limit of normal for 7 years, and symptoms of excessive glucocorticoid production (such as moon face and obesity) were gradually improved. On the other hand, the size of both adrenal glands gradually increased despite treatment with trilostane. Though trilostane therapy could not prevent adrenal growth, it did suppress cortisol secretion over the long term, so it might be a reasonable option for AIMAH in addition to adrenalectomy.
    Internal Medicine 01/2011; 50(21):2621-5. · 0.97 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: IntroductionTo investigate the clinical significance of the serum adiponectin concentration in Japanese diabetic patients. MethodsWe examined serum adiponectin levels in 1,541 diabetic patients from 2005 to 2009. ResultsThe serum level of adiponectin was higher in patients with type 1 diabetes and in those receiving pioglitazone treatment than in other groups. Serum adiponectin was inversely correlated with body mass index, waist circumference, fasting plasma glucose, serum triglycerides, serum uric acid, fasting serum IRI, and HOMA-IR; it was positively correlated with age and HDL cholesterol. Serum adiponectin was significantly lower in diabetic male patients with metabolic syndrome than in those without it, and patients with more cardiometabolic risk factors also had lower adiponectin levels. Serum adiponectin was significantly lower in patients with microangiopathy than in those without (both male and female), and was also significantly lower in male patients with macroangiopathy than in those without it. ConclusionsMeasurement of the serum adiponectin in diabetic patients is useful for assessing metabolic status and for evaluating the risk of arteriosclerosis, particularly in males. KeywordsAdiponectin–Metabolic syndrome–Cardiometabolic risk–Diabetes mellitus
    01/2011; 2(2):65-71.
  • [Show abstract] [Hide abstract]
    ABSTRACT: A 27-year-old woman with severe proteinuria, diabetes mellitus, sensorineural hearing impairment, and slight renal dysfunction was admitted to our hospital. The patient was diagnosed as having mitochondrial kidney disease, a rare disease with mitochondrial 3243 A to G mutation. The patient’s mother and younger sister had the same mitochondrial mutation, with the younger sister also having proteinuria. Differing from general mitochondrial diabetic patients with decreased insulin secretion, this patient showed insulin resistance. The thickening of the carotid intima-media, high brachial ankle pulse wave velocity, and ischemic change in cerebral white matter implied progressive arteriosclerosis. The patient also had hypoadiponectinemia even though she only had a small amount of visceral fat, and this hypoadiponectinemia may be one of the reasons behind the insulin resistance and arteriosclerosis. This case showed that insulin resistance cannot be the sole reason to exclude the possibility of mitochondrial kidney disease, and also showed the potential relationship between mitochondrial mutation and hypoadiponectinemia.
    Diabetology International. 3(1).